<SEC-DOCUMENT>0001144204-13-066182.txt : 20131209
<SEC-HEADER>0001144204-13-066182.hdr.sgml : 20131209
<ACCEPTANCE-DATETIME>20131209060732
ACCESSION NUMBER:		0001144204-13-066182
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20131207
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131209
DATE AS OF CHANGE:		20131209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		131264362

	BUSINESS ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v362486_8-k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (date of earliest event reported):
<B>December 7, 2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nevada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt; text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>01-12584</B></FONT></TD>
    <TD STYLE="width: 50%; padding-right: 0.8pt; text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>13-3808303</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">155 Gibbs Street, Ste. 412</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Address
of principal executive offices and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(734) 332-7800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;(Registrant&rsquo;s
telephone number including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name and Former Address)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 88%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item&nbsp;7.01.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Regulation FD Disclosure. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 7, 2013, Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;)
issued a press release announcing its entry into worldwide license and option agreements with Cedars-Sinai Medical Center (&quot;Cedars-Sinai&quot;)
for the development of new treatment approaches to target non-bacterial intestinal microorganism life forms known as archaea that
are associated with intestinal methane production and chronic diseases such as irritable bowel syndrome (IBS), obesity and type
2 diabetes, through its newly formed subsidiary, Synthetic Biomics, Inc. In addition, the Company announced that its Chief Executive
Officer, Jeffrey Riley, will host a conference call on Monday, December 9<SUP>th</SUP> at 9:00 a.m. EST, during which, Mark Pimentel,
M.D., FRCP&copy;, Director of the Gastrointestinal Motility Program at Cedars-Sinai, will provide an audio-visual presentation
overview of the scientific basis and market opportunity of our new pathogen-specific approaches to archaea-associated diseases,
such as, constipation-predominant IBS (C-IBS), obesity and diabetes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The press release attached as Exhibit 99.1 to this Report includes
&ldquo;safe harbor&rdquo; language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that
certain statements contained in the press release are &ldquo;forward-looking&rdquo; rather than historical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information included in this Item 7.01 and in Exhibit 99.1
shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The Company
undertakes no duty or obligation to update or revise information included in this Report or any of the Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item&nbsp;9.01.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Financial Statements and Exhibits. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As described above, the following exhibit is furnished as part
of this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.75in; text-indent: 0in; text-align: justify">Exhibit&nbsp;99.1
&ndash; Press release, dated December 7, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.75in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.75in; text-indent: 0in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.75in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: December 9, 2013</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Registrant)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 40%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v362486_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">EXHIBIT 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Enters into License
with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Webcast to be held Monday, December
9<SUP>th</SUP> at 9:00 a.m. EST --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD, December 7, 2013 &ndash;</B>
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious
infectious diseases and other diseases, announced today that it entered into worldwide license and option agreements with Cedars-Sinai
Medical Center (&ldquo;Cedars-Sinai&rdquo;) for the development of new treatment approaches to target non-bacterial intestinal
microorganism life forms known as archaea that are associated with intestinal methane production and chronic diseases such as irritable
bowel syndrome (IBS), obesity and type 2 diabetes, through its newly formed subsidiary, Synthetic Biomics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cedars-Sinai investigators have discovered
that eradicating archaea and inhibiting intestinal methane production may treat the underlying cause of major diseases not typically
considered forms of infectious diseases. IBS, one of the most prevalent chronic diseases, affects approximately 40 million Americans
(an estimated 16 million of which have the archaea-associated constipation-predominant form of the disease (C-IBS)). Obesity affects
over one-third (35.7%) of adult Americans according to the Centers for Disease Control (CDC). Diabetes affects an estimated 25.8
million Americans according to the CDC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ongoing efforts include formulating and
clinically testing non-antibiotic FDA-approved oral drug candidates for ultimate product registration via potential expedited pathways.
Such candidates are intended for the specific eradication of gastrointestinal archaea and prevention of their recolonization, with
the goal of having little or no impact on a patient&rsquo;s normal bacterial microflora. These efforts are being led by Mark Pimentel,
M.D., FRCP(C), Director of the Gastrointestinal Motility Program at Cedars-Sinai Medical Center, who is credited with discovering
that IBS is a form of infectious disease, in which gut microflora that should normally be confined to the large intestine inappropriately
colonize the small intestine. This process is referred to as small intestinal bacterial overgrowth (SIBO), which results in gas,
bloating, abdominal pain and altered stool habits characterized by IBS. The Company licensed and optioned from Cedars-Sinai a portfolio
of intellectual property comprised of several U.S. and international patents and pending patent applications for various fields
of use, including C-IBS, obesity and diabetes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;We are pleased to initiate this exciting
new anti-infective approach to treat these major archaea-implicated disease indications with Cedars-Sinai along with Dr. Pimentel&rsquo;s
leadership,&rdquo; said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics, Inc. &quot;This program complements our
current microbiome focus and expertise, which includes development of an oral biologic to protect the microbiome from the effects
of hospital administered IV antibiotics for the prevention of <I>C. diff</I> infection.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Pimentel stated, &ldquo;Since uncovering
the fundamental role that small intestinal bacterial overgrowth plays in IBS, our group has continued to uncover and increasingly
appreciate the role that intestinal archaea play in highly prevalent diseases areas including, C-IBS, obesity, and type 2 diabetes.
I am excited to be working with Synthetic Biologics and its newly formed subsidiary, Synthetic Biomics, to develop potential breakthrough
pathogen-specific approaches for these major disease indications.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Synthetic Biologics&rsquo; Conference Call</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics&rsquo; Chief Executive
Officer, Jeffrey Riley, will host a conference call on Monday, December 9<SUP>th</SUP> at 9:00 a.m. EST. During the call, Mark
Pimentel, M.D., FRCP(C), Director of the Gastrointestinal Motility Program at Cedars-Sinai, will provide an audio-visual presentation
overview of the scientific basis and market opportunity of our new pathogen-specific approaches to archaea-associated diseases,
such as, C-IBS, obesity and diabetes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interested parties should call 1-877-870-4263,
(U.S. toll free), 1-855-669-9657 (Canada toll free), or +1-412-317-0790 (International), fifteen minutes before the start of the
call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question &amp; Answer Session.
The call will also be webcast over the Internet with a slide presentation at <FONT STYLE="color: blue"><U>http://www.videonewswire.com/event.asp?id=97322</U></FONT></TT>.
If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, <FONT STYLE="color: blue"><U>http://www.videonewswire.com/event.asp?id=97322</U></FONT></TT>
for 30 days after the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Cedars-Sinai Medical Center</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Cedars-Sinai is
internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well
as advances in biomedical research and innovative medical education programs. For more than 20 years, Los Angeles-area residents
have named Cedars-Sinai the &quot;Most Preferred Hospital for All Health Needs&quot; in National Research Corporation's annual
Healthcare Market Guide survey. Cedars-Sinai Medical Group and Cedars-Sinai Health Associates both ranked among the top 10 physician
groups in Southern California by Integrated Health Care Associates (IHA), a California leadership group of health plans, physician
groups, and health systems. Today, Cedars-Sinai is committed to providing superior outpatient, acute and sub-acute patient care,
breakthrough biomedical research, graduate and undergraduate medical education and community service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE MKT: SYN)
is a biotechnology company focused on the development of product candidates for serious infectious diseases and other diseases.
Synthetic Biologics is developing oral treatments targeting archaea, a non-bacterial intestinal form of life increasingly associated
with chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes, an oral biologic to protect the gastrointestinal
microflora from the effects of IV antibiotics for the prevention of <I>C. diff</I> infection, and a series of monoclonal antibodies
(mAbs) for the treatment of Pertussis and <I>Acinetobacter</I> infections. In addition, the Company is developing an oral estriol
drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS (with results
of an ongoing 164 subject, 15 center, two-year, double blind, placebo controlled, Phase II relapsing-remitting MS clinical trial
expected to be announced during the first half of 2014). For more information, please visit Synthetic Biologics' website at <FONT STYLE="color: Blue"><U>www.syntheticbiologics.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release includes forward-looking
statements on Synthetic Biologics' current expectations and projections about future events. In some cases forward-looking statements
can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot;
&quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions.
These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties,
many of which are difficult to predict and include statements regarding the potential for the new anti-infective program and the
role of the microbiome in C. difficile</I> and C-IBS<I>. The forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important
factors that could cause actual results to differ materially from those reflected in Synthetic Biologics' forward-looking statements
include, among others, our inability to obtain financing on acceptable terms to permit us to timely commence or complete the clinical
trials and discovery programs consistent with our current expectations, our inability to successfully develop, receive regulatory
approvals for or to commercialize new product candidates or achieve desired results from the new anti-infective program and other
factors described in Synthetic Biologics' report on Form 10-K for the year ended December 31, 2012 and any other filings with the
SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation
to update any forward-looking statements contained in this release on account of new information, future events, or otherwise,
except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Kris Maly</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vice President, Corporate Communication</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(734) 332-7800, ext. 22</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!``44#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBL&_\`
M$!20PV2AV!P9#R,^P[T`;U)FN;@MM5OB'DN'5<]-V!^E%YX9N;F<W":G.DAP
M-H8A0/05E6G.$;PCS&E*,9.TI6.EHKF!I'B&TYMM7\T#^&49_G3I-=U/2H(V
MU33FE!8AI+?^$#&#C\ZBC7E4ER.#3\]OO-)8=)7A)/\`/\3I:*H:;K%CJL>^
MSN%D(^\AX9?J.M7LUT-6W,&FG9BT444""BBO*_B9\1+S1KXZ)HSB*X5`UQ<D
M`E,C(5<\9QSGW%`'JE%?/%IX6^(.O6JZFCWSI(-Z-->[&<'N`3_A4>G>-O%O
M@[5C:ZA+<S+$0)K.\;<<?[+'D>Q!Q0!]%T5XO\0;_6X8;'Q-H>M:@FD:C&I,
M:3$"%R.F.P/\P:Z+X5>,Y-=T^32]2G:74;4;ED<Y::,GJ?4@\'\*`/1J*XKX
ME>+CX9\/F.UDVZE>9C@QU0?Q/^';W(KA_AF_B7Q)KAN;S6]1?3++#2AISB5_
MX4_J?_KT`>VT5\PR>-/$\5Z[)KU_\DI*JTQ*\-T(]/:OH'PEXD@\4Z!!J,6%
ME(V3Q`_ZN0=1].X]C0!NT5Y7\8M9U329-'_LW4+FT\T3;_)D*[L;,9_,USK:
MAXRU+P-HESI5UJUS<&XNEN)(&9F(!7:&(_''XT`>[45\W7VH_$#3+;[1?W>N
M6T&0OF2NRKD]!FH=/UOQQJSR)IVI:S=M&`7$,C-M!Z9H`^EZ*\1\+R^.8=1N
MY=7?64M$L+AMUP6"JX3Y3SWSTK,^'_B?7[[QMI5M=ZS?3P2.P>.28E6^0GD4
M`?0-%%>(?%3Q%K6F>,S;V&JWEM!]FC;RXI2JY);)Q0![?17BGB?Q#K-M\-?"
MEY!JMW'=7!;SIEE(:3@]3WKEM/U;Q[JT;R:=?:W=(C;6:%V8*?0T`?2E%?.W
M_%S?7Q%_X_6I'_PL+_A%+C<==^W?;X]F=V_RO+?./;.W\<4`>ZT5\X7=Y\1+
M"U>ZO+C7H+>/&^21F"KDXY/UJI8:_P"-=5G:#3]4U>ZE5=Y2&5F(7IG]10!]
M-45XCX0_X3[_`(2[3?[4.M_8?-/G>?NV8VGKGWQ7.'Q9XB_X2LP?VY?^3_:/
ME[/..-OFXQCTQQ0!](T5SGC+Q=:^$-'^U2KYMS*2EO`#C>WOZ`=S7B,GB'QK
MXUU!XK:XO9F^]]GLB8TC'OC'YDT`?2-%?-EW!XY\(%+FXDU.S0G`D\XO'GT/
M)'YUZA\.?B&_B<OIFIA$U.--ZN@PLZCJ<=F'<4`>AT444`9^M3M!I<K(<,V$
M!^M86B6JS3AF'?'X#K6]K,!N-+F51EE&\?A6)HLXC923PK<_0TP.I````&`.
MU+0**0!2%0000"#U!I:*`.=U3PK;W,GVJP8V=XO*O&<<U6TSQ+/:7@TS7D$4
M^=L=QC"OZ9]#[]*ZNLC7]$CUJS\H[!(OW6(_3-:*5])&T9J7NSV_(UZ*X_PE
MJEVOF6-_<1/#"XA@E)Y=^?DSW("GCK78"H:L[$5(.$K,*^>_BSH=U8>+[C4)
M(V-G?!6CEQP&"@%2>QXS^-?0E>>ZA\4?"TE[/H]_8WD@68V\JRVZ-'D-M).6
MZ9]J1!S/A_XS-965O9ZMIAE$2+&)[9@"0!CE3W^AK:>_^'/C_5(IKQRM^4$2
M).SPEADD#@X)Y]:U-3^$WA74-S0V\UDY[VTA`_[Y.17DWCKP/+X-N[=?M0NK
M6ZW>4Y7:P*XR"/Q'-`'O+^%M+;PLWAU82-/,9C52Q8IDY!!/<'D5\\XU/P%X
MRQG;=V,O7HLJ'^C+_GBO:OA5JUUJW@B%KMVDDMI6MP[')95P1D]^#C\*YWXV
MZ;;?V=IVJ!,78F\@N/XD(+8/T(X^IH`\ZUS5=0\=^+A)%$QEN76&U@SGRU[#
M^9)^M?0OAGP_;>&=`M],M\'RUS))CF1S]YO\]L5YA\$M*M9[S4]4D7=<VVR&
M(GHH8$L1[\8KV<]*`/E/3=-.L>)8=-$GEFZN6B#D9VDDXKHO`_B*Y\#^+9;/
M40T5M))Y%[&?^6;`X#_A_(UF>$/^2B:3_P!A`?S->A_&#PAYT`\264?[R,!+
MQ5'WDZ!_PZ'V^E`%;XXL';064@J5F((/!^Y73_"#_D0(/^OB7_T*O%=4\0W&
MK:#I.G7.6?3?,1)2?O1MMV@^XP1],5[7\(/^1`@_Z^)?_0J8$?QB_P"1$;_K
MZB_K7*_`[_D)ZS_UQB_FU=5\8O\`D1&_Z^HOZUROP._Y">L_]<8OYM2`]8U[
M_D7=3_Z])?\`T`U\T>$]8BT#Q)8:I-$\L=N2S(F-QRI'&?K7TQK_`/R+FI_]
M>DO_`*`:^;/!6EVNM>+--TZ]1GMIV(=58J3A2>H]Q0!ZE_PN_2?^@3??]])_
MC7FOCCQ)!XJ\1'4[:"6"/R4CV2$9R,\\?6O8O^%2>$?^?.X_\"7_`,:\E^(N
M@V'ASQ4;#38WCM_LZ2;6<L<G.>3]*`-;Q;_R2GP;]7_D:?\`#CQWI7A'3+VV
MU"*Z=YYQ(IA0,,;0.<D4SQ;_`,DI\&_5_P"1JW\,?!>B^*-*OKC5()))(9PB
M%)63`V@]J`.L_P"%T>&O^?;4?^_*_P#Q5=AX=\06GB;2$U*R258'=D`E4!L@
MX/`)KG/^%2>$?^?.X_\``E_\:Z?0]#L?#NF+I^G1LENK,P5G+').3R:`,+XG
M_P#).M6_W8__`$8M>;?!7_D<;O\`Z\6_]#2O2OBA_P`DYU;_`'8__1BUYK\%
M?^1QN_\`KQ;_`-#2@#WBOE8_\CD?^PI_[6KZIKY5/_(Y'_L*?^UJ`.F^+VI2
M7?CB2V9OW5G"D:#T)&YC^H_*O6?AUHL&C>"[`)&!/<QBXG?'+,PR,_08%>2?
M%S3Y+3QW/,RD1WD*2(?7`VG]1^M>O_#[6(=8\%:=)&X,D$0MYESRK*,<_A@_
MC0!O7]E;ZC83V5U&)()T,;J1G(-</H/PHT_P_K=IJEMJMZ\MNQ(5PN&!!!!P
M/0UW-]>0Z?87%Y<.$A@C:1V)Z`#->7>&_BSJFO\`B.QTL:1;(ES+M9ED8E4P
M23^`%`'K-%%%``:YK5,:!:RS1[2L\Z@*1G"X.172U4OM.M=114NH1(JDE021
M@XQFLZT92@XP=F*5[:&99:^KB.-X<AL!6C/'ZUN@YK@M3T>\T)FDB#W.GDYR
M.6C^O^-6M+\3O%&H+?:(/K\RUYE'%U*,O9XG[S-5+:2.THJA::S8WF!'.JO_
M`''^4U?KU8SC-7B[FB:>P4E+69>:_IMC:RSS72$1,4*J<L6'50/6KC%R=DB9
MU(P5Y.QXQ\0F;3O&LMWIER55WCNL1/\`+YH[D#C.0?S->W:5?KJ>D6=\G"W$
M*R8],C.*\6US3F\273:MIT4$"RNWVJ*2=$$+]B2Q'##!^N:]:\)V5YIWAJRL
M;V*-);>,1_NY-X8=CG`_*L(TZE.K*,U8]S&UL+B,#0J49INWSMYKY&W7C?Q&
M^&M_<:I/K6B0_:%N#ON+9?OA^[*.X/IUS7LE9=WXDT2PNGMKO5+2"=,;TDE"
ME<C(SZ<5L>,>%V/CWQMH-NM@WG,L0V*MW:EF7VS@$_C4#V'C3X@ZG'+<6]Q,
M1\JRRQ^5#$.^.`/RR37T:K)*BNC*ZL,JP.01ZBG4`8WA7P_#X8\/6VEQ/YAC
M!:23&-[GEC_GM7)_&&PO-0\-V,=E:3W+K=ABL,9<@;6YP*]!GGBM;>2>>18X
M8U+.['`4#J2:>K!E#*<@C(([T`>7_!G3;[3K36!?65Q;%Y8B@FC*;L*>F:]1
M/2BFR2QPQM)*ZI&@+,S'`4>I-`'SKX5T'6(/'NF3S:3?1PI?;FD>W8*!D\DX
MZ5]$S11SPO#*BO'(I5U89#`]0:HZ=KVDZM(\>GZA;W,B#<RQN"<>N/3WK1H`
M^;_%G@+5-$\03VUA875U8M^\MY(HF?"'^$D#J.E>M_"JTN;'P/##=V\MO*)Y
M28Y4*M@MQP:[6H3=0+=K:F9!<,AD6//S%0<$X],D4`<9\6+.ZOO!1AL[::XE
M^TQG9$A9L<\X%<U\&M+U#3]1U9KVPN;97BC"F:)D#8+=,UZ]10!0UM'ET#48
MXU+.UK*JJHR22IX%>#_#W0M8M/'.DSW.E7L,2.VZ22!E5?D;J2*^AB0H))``
MY)/:LVR\0Z-J5T;6RU.UGG`)V1R`D@=<>OX4`:=>%_%?1M4OO&IFM--N[B+[
M+&-\4+,N<MQD"O=**`/#_%.CZI/\,O"=M%IUW)/"6\V)(6+)P>HQQ7+Z6OC?
M18I(M,MM8M8Y&W.L=NP!/3/2OI"]OK33K5KF]N(K>!>LDC!0*CT_5;#5H6EL
M+N&Y16VL8VSM/H?2@#P'^U_B3_STU[_OPW_Q->A?"V\\374VICQ"U^558_)^
MUQE?[V<9`]J](HH`Y7XCVT]YX!U2"VADFF=4VQQJ68_O%/`%>>_"'2-3T_Q9
M=2WNG7=M&;)E#S0L@)WIQDBO9X[F"6>:&.5&EA($B`\H2,C/IQ4M`!7S.?#V
MM_\`"6F7^Q[_`,O^TM^_[.V-OFYSG'3%?3%9E[XAT;3KL6MYJ=K!.<'9)(`1
MGIGT_&@#+\;^#K?QAI(@+B&\@):WG(R%/<'_`&37B0L?&7@._D>&&\M&/#20
MIYD4H_(@_CS7TF""`000>XI:`/FN_P!=\:>,56QF^VW<9(_<06^Q6/O@#/XU
MZ=\-OA]+X<+:MJH7^TI$V1Q*<B!3UY[L?TKT.66*WA>65TBB0%F=B`JCN2:I
MZ;K>EZN9!I]]!<F/&\1N"1GH<>E`%^BBB@`HHHH`0C/6N=U3P?8WKM/:LUE<
MGG?%]TGW7_"NB)I"V*BI3A45I*XG%2T9YO>Z#K]AG=:)>Q#^.W/S?]\UE_\`
M"07-@=C27UH1_"X88KU66\2$9;=^"DU3;5K*<^4\<C^S0,1^HKB>703O!M&$
ML.NCL<)I'C-#J`-]K$BQJC%1)G8SXX!('`K&O[/4!`]XD`N(F))N8&$J$GG.
M5_K7K"6FG2D,+"WSZF`#^E7(HXXDVQQHB^BJ`*]+`5)X2Z^*_?<XL7E:Q44I
MR>FQYAX2^'0N;N#6=8,<D0(EA@!W;SU!8],>WYUZI3414&%4*/0#%.JZU:5:
M7-([<-AX8>')$*\WO)W3Q/XKB36=(L-[0@K?H&+?N%Y&6''X&O2*K2Z?9SR&
M2:TMY'/5GC!/YD5D=!E^#'5_!ND%('A46R*J.V3@#&<^AQD>QK=H`P,"B@#$
M\8X_X0O6\_\`/C-_Z`:U;/\`X\;?_KFO\JD=%D0HZAE88*D9!%*``,#I0`M<
MSXZ0MX?1I$9[)+N![U5!.8`X+Y`ZCH3[`UTU!`(P>0:`..U6[TW4/$/AQ=(G
MMY[V.X,A:V8-LMMC!]Q'13E0`>IQ78U7MK"SLRYM;6"`N<MY487=]<=:L4`%
M<GJ5[:6/Q%L)+RZ@MT.F3`--($!/F)QDUUE03V=M=$&XMX92.GF(&Q^=`#K:
MZM[R!9[:>*>)ONR1.&4_B*EID,,4$8CAC2-!T5%``_`4^@#`\:Q3S>#M32V6
M1W,0W+']YDW#>!CN5W5CZY>Z-?VFA0:)-:S7?VR![);8@M&@8%S@<JNS<#GU
MQ7;U6@T^SMIGF@M((I9/OO'&%9OJ1UH`LT444`<KXE>"W\3>'KG42BZ:C3`O
M)_JTG*CRRV>!QO`)[FJV@ZFESXYU"W(TR6<V:O)<V);D!\*K9."0#U'(S782
MPQSQ-%-&DD;##(Z@@CW!J.WL[:T0);6\,*J,!8T"@#\*`)Z***`.>T7'_"5^
M)O\`KK;_`/HD5T--6-59F"J&;[Q`Y/UIU`!7"Z/?Z-8:;K\.N2VR77VRX:]C
MG(#2H2=F`>64IM`Q]*[JJTUA9W,Z3SVD$LJ?<D>,,R_0GI0!%HOE?V)8^1;2
MVT/D)L@E.7C7`PIY/(%7J**`,+QBEG)X5O8]0DFCM6"B26%=QC^888CNH."?
M;-8VCWS'Q?:P7$^EZI-)9R;+ZQ&UXXP5.)%!*X)Q@YZ@UVK`,I4@$'@@]Z@M
9;"TLMWV2U@@WG+>5&%W?7%`%BBBB@#__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
